{"gene":"AVPR1B","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2010,"finding":"AVPR1B (Avpr1b) receptor on anterior pituitary corticotrophs mediates AVP-stimulated ACTH release; pharmacological antagonism or genetic knockout of Avpr1b significantly reduces plasma ACTH (and corticosterone) responses to acute restraint and forced swimming stress, demonstrating its essential role in HPA axis activation.","method":"Avpr1b knockout mice compared to wild-type; pharmacological antagonism with a selective Avpr1b antagonist; plasma ACTH and corticosterone measurement by ELISA","journal":"Journal of neuroendocrinology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal genetic KO and pharmacological blockade with defined neuroendocrine phenotype, replicated across two stressor paradigms","pmids":["20846299"],"is_preprint":false},{"year":2008,"finding":"Avpr1b in the dorsal hippocampus mediates anxiety-related behavior (open-arm avoidance in elevated plus-maze); selective Avpr1b antagonist (SSR 149415) microinfused into the dorsal (but not ventral) hippocampus reduced anxiety-like behavior, while Avpr1a antagonism had the opposite regional specificity (ventral but not dorsal hippocampus).","method":"Intra-hippocampal microinfusion of selective receptor antagonists; elevated plus-maze and shock-probe burying behavioral tests in rats","journal":"Neuropeptides","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization-function experiment with pharmacological dissection, single lab","pmids":["18508119"],"is_preprint":false},{"year":2013,"finding":"AVPR1B is dramatically upregulated in pituitary corticotropinoma cells relative to normal pituitary, and desmopressin (a synthetic AVP receptor agonist) directly stimulates ACTH secretion, intracellular Ca2+ mobilization, and proliferation exclusively in corticotropinoma cells via AVPR1B; an AVPR1B antagonist completely blocked these stimulatory effects.","method":"Quantitative RT-PCR for AVPR expression; primary cultures of corticotropinoma and other pituitary adenoma cells treated with desmopressin; ACTH secretion assay; [Ca2+]i kinetics; AVPR1B antagonist blockade","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal assays (qPCR, Ca2+ imaging, ACTH secretion, pharmacological blockade) in primary human tumor cells","pmids":["23884782"],"is_preprint":false},{"year":2013,"finding":"V1bR (AVPR1B) blockade with the selective antagonist Nelivaptan reduces the increase in blood ACTH caused by acute heat stress in rats, directly confirming AVP's positive role in regulating ACTH secretion from the pituitary via V1bR; heat exposure also decreased intrapituitary V1bR protein levels.","method":"Pharmacological blockade with Nelivaptan (selective V1bR antagonist) in rats; circulating ACTH and corticosterone by ELISA/chemiluminescence; intrapituitary ACTH and V1bR protein by western blot","journal":"The Journal of experimental biology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological blockade with defined neuroendocrine readout, single lab","pmids":["23580725"],"is_preprint":false},{"year":2022,"finding":"USP8 mutations in corticotropinomas enhance AVPR1B promoter activity, leading to upregulation of AVPR1B expression and increased ACTH responsiveness to desmopressin (DDAVP); mutant USP8 overexpression increases Avpr1b promoter activity compared to wild-type USP8.","method":"Quantitative RT-PCR and immunohistochemistry for AVP receptor expression; dual-luciferase reporter assay for Avpr1b promoter activity with mutant vs. wild-type USP8 overexpression","journal":"Pituitary","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay with functional USP8 mutant/WT comparison, single lab","pmids":["35451730"],"is_preprint":false},{"year":2024,"finding":"AVPR1B (V1bR) is expressed exclusively in pancreatic alpha cells (not beta cells); activation of V1bR by AVP stimulates alpha cells to secrete glucagon, which then promotes glucose-dependent insulin secretion from beta cells in a paracrine manner by activating GLP-1R (not GCGR), revealing an AVP/V1bR → glucagon → GLP-1R crosstalk between alpha and beta cells.","method":"Single-cell transcriptome analysis for receptor localization; V1bR selective antagonist blockade; islet vs. isolated beta-cell insulin secretion assays; glucagon measurement; GLP-1R vs. GCGR antagonist experiments","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (scRNA-seq, pharmacological, cell-type-specific assays), single lab","pmids":["39217353"],"is_preprint":false}],"current_model":"AVPR1B encodes a G protein-coupled vasopressin receptor expressed on anterior pituitary corticotrophs (where it mediates AVP-stimulated ACTH release and HPA axis activation during stress), in hippocampal neurons (where dorsal hippocampal AVPR1B modulates anxiety-like behavior), and in pancreatic alpha cells (where it triggers glucagon secretion that promotes paracrine GLP-1R-dependent insulin release from beta cells); in corticotropinomas, AVPR1B is dramatically upregulated—an effect enhanced by USP8 mutations that increase AVPR1B promoter activity—making it the primary mediator of desmopressin-induced ACTH hypersecretion in Cushing's disease."},"narrative":{"teleology":[{"year":2008,"claim":"The question of where in the brain AVPR1B acts to regulate anxiety was addressed by showing that dorsal hippocampal AVPR1B mediates anxiety-like behavior, establishing region-specific functional roles for vasopressin receptor subtypes.","evidence":"Intra-hippocampal microinfusion of selective AVPR1B antagonist (SSR 149415) with elevated plus-maze and shock-probe behavioral tests in rats","pmids":["18508119"],"confidence":"Medium","gaps":["Single lab finding; independent replication in additional behavioral paradigms needed","Downstream signaling cascades in hippocampal neurons not characterized","Whether dorsal hippocampal AVPR1B affects HPA axis feedback remains untested"]},{"year":2010,"claim":"The necessity of AVPR1B for stress-induced HPA axis activation was established by demonstrating that both genetic knockout and pharmacological antagonism of Avpr1b markedly reduce ACTH and corticosterone responses to acute stress.","evidence":"Avpr1b knockout mice and selective V1bR antagonist treatment with plasma ACTH/corticosterone measurement across restraint and forced-swim stress paradigms","pmids":["20846299"],"confidence":"High","gaps":["Whether AVPR1B is required for chronic stress responses not addressed","Intracellular signaling pathway (Gq, Ca²⁺, PKC) in corticotrophs not dissected in vivo"]},{"year":2013,"claim":"AVPR1B was identified as the key receptor mediating desmopressin-induced ACTH hypersecretion in human corticotropinomas, explaining why the desmopressin stimulation test selectively detects Cushing's disease: AVPR1B is massively overexpressed in corticotropinomas relative to normal pituitary.","evidence":"qRT-PCR for receptor expression, primary corticotropinoma cell cultures with desmopressin stimulation, ACTH secretion assays, intracellular Ca²⁺ imaging, and AVPR1B antagonist blockade; corroborated by V1bR antagonist Nelivaptan reducing heat-stress-induced ACTH in rats","pmids":["23884782","23580725"],"confidence":"High","gaps":["Mechanism driving AVPR1B upregulation in tumors was not yet identified","Whether AVPR1B-mediated proliferation is sufficient for tumorigenesis remains unknown"]},{"year":2022,"claim":"A mechanism for AVPR1B overexpression in corticotropinomas was revealed: recurrent USP8 mutations enhance AVPR1B promoter activity, linking a frequent somatic driver mutation to the receptor upregulation underlying desmopressin responsiveness.","evidence":"Dual-luciferase reporter assay comparing mutant vs. wild-type USP8 effects on Avpr1b promoter activity; qRT-PCR and immunohistochemistry in tumor samples","pmids":["35451730"],"confidence":"Medium","gaps":["Single-lab reporter assay; independent validation and identification of the transcription factor intermediaries needed","Whether USP8-driven AVPR1B upregulation is necessary and sufficient for desmopressin sensitivity in vivo not shown","The direct USP8 substrate linking deubiquitination to AVPR1B promoter activation is unidentified"]},{"year":2024,"claim":"AVPR1B function was extended beyond the pituitary and brain by showing it is the exclusive vasopressin receptor in pancreatic alpha cells, where it triggers glucagon release that drives paracrine GLP-1R-dependent insulin secretion from beta cells.","evidence":"Single-cell transcriptomics for receptor localization; islet vs. isolated beta-cell insulin secretion assays; V1bR, GLP-1R, and GCGR selective antagonist experiments","pmids":["39217353"],"confidence":"Medium","gaps":["Single-lab finding; in vivo confirmation of AVP/AVPR1B-glucagon-GLP-1R axis in glucose homeostasis needed","Physiological relevance under fasting vs. fed states not delineated","Whether AVPR1B in alpha cells contributes to diabetes pathophysiology is unexplored"]},{"year":null,"claim":"The structural basis of AVPR1B selective agonism/antagonism, the full downstream signaling network in corticotrophs (beyond Ca²⁺ mobilization), and the therapeutic potential of AVPR1B-targeted therapy in Cushing's disease and metabolic disorders remain to be established.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of AVPR1B in complex with ligand or G protein is available","Complete Gq/Ca²⁺/PKC signaling cascade in corticotrophs not mapped","Clinical efficacy of selective AVPR1B antagonists in Cushing's disease not demonstrated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2,5]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2,5]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,5]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[1]}],"complexes":[],"partners":["USP8"],"other_free_text":[]},"mechanistic_narrative":"AVPR1B is a Gq/11-coupled vasopressin receptor that functions as a critical mediator of hypothalamic-pituitary-adrenal (HPA) axis activation and paracrine hormone signaling in the endocrine pancreas. In anterior pituitary corticotrophs, AVPR1B mediates arginine vasopressin (AVP)-stimulated ACTH release, and its genetic knockout or pharmacological antagonism significantly attenuates plasma ACTH and corticosterone responses to acute stress [PMID:20846299, PMID:23580725]. AVPR1B is dramatically upregulated in corticotropinomas—an effect potentiated by USP8 mutations that enhance AVPR1B promoter activity—where it drives desmopressin-stimulated ACTH hypersecretion, intracellular Ca²⁺ mobilization, and cell proliferation [PMID:23884782, PMID:35451730]. In pancreatic islets, AVPR1B is expressed exclusively in alpha cells, where its activation by AVP stimulates glucagon secretion that promotes glucose-dependent insulin release from beta cells through a paracrine GLP-1R-dependent mechanism [PMID:39217353]."},"prefetch_data":{"uniprot":{"accession":"P47901","full_name":"Vasopressin V1b receptor","aliases":["AVPR V1b","AVPR V3","Antidiuretic hormone receptor 1b","Vasopressin V3 receptor"],"length_aa":424,"mass_kda":47.0,"function":"Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system (Microbial infection) During SARS coronavirus-2/SARS-CoV-2 infection, may recognize and internalize the complex formed by AVP/Arg-vasopressin, SARS-CoV-2 spike protein and secreted ACE2 through DNM2/dynamin 2-dependent endocytosis","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P47901/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AVPR1B","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AVPR1B","total_profiled":1310},"omim":[{"mim_id":"600821","title":"ARGININE VASOPRESSIN RECEPTOR 1A; AVPR1A","url":"https://www.omim.org/entry/600821"},{"mim_id":"600264","title":"ARGININE VASOPRESSIN RECEPTOR 1B; AVPR1B","url":"https://www.omim.org/entry/600264"},{"mim_id":"219080","title":"ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA 1; AIMAH1","url":"https://www.omim.org/entry/219080"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"pituitary gland","ntpm":13.8}],"url":"https://www.proteinatlas.org/search/AVPR1B"},"hgnc":{"alias_symbol":["V1bR","VPR3"],"prev_symbol":["AVPR3"]},"alphafold":{"accession":"P47901","domains":[{"cath_id":"1.20.1070.10","chopping":"32-240_273-350","consensus_level":"high","plddt":88.7963,"start":32,"end":350}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P47901","model_url":"https://alphafold.ebi.ac.uk/files/AF-P47901-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P47901-F1-predicted_aligned_error_v6.png","plddt_mean":73.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AVPR1B","jax_strain_url":"https://www.jax.org/strain/search?query=AVPR1B"},"sequence":{"accession":"P47901","fasta_url":"https://rest.uniprot.org/uniprotkb/P47901.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P47901/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P47901"}},"corpus_meta":[{"pmid":"20828336","id":"PMC_20828336","title":"The vasopressin Avpr1b receptor: molecular and pharmacological studies.","date":"2010","source":"Stress (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/20828336","citation_count":86,"is_preprint":false},{"pmid":"18384079","id":"PMC_18384079","title":"Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder.","date":"2008","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18384079","citation_count":81,"is_preprint":false},{"pmid":"17909131","id":"PMC_17909131","title":"Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders.","date":"2007","source":"Archives of general psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/17909131","citation_count":62,"is_preprint":false},{"pmid":"23884782","id":"PMC_23884782","title":"A cellular and molecular basis for the selective desmopressin-induced ACTH release in Cushing disease patients: key role of AVPR1b receptor and potential therapeutic implications.","date":"2013","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23884782","citation_count":57,"is_preprint":false},{"pmid":"27920663","id":"PMC_27920663","title":"ASD and Genetic Associations with Receptors for Oxytocin and Vasopressin-AVPR1A, AVPR1B, and OXTR.","date":"2016","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27920663","citation_count":40,"is_preprint":false},{"pmid":"23422793","id":"PMC_23422793","title":"Family-based study of AVPR1B association and interaction with stressful life events on depression and anxiety in suicide attempts.","date":"2013","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23422793","citation_count":24,"is_preprint":false},{"pmid":"18508119","id":"PMC_18508119","title":"Dissociation of the anxiolytic-like effects of Avpr1a and Avpr1b receptor antagonists in the dorsal and ventral hippocampus.","date":"2008","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/18508119","citation_count":24,"is_preprint":false},{"pmid":"20846299","id":"PMC_20846299","title":"Attenuated stress response to acute restraint and forced swimming stress in arginine vasopressin 1b receptor subtype (Avpr1b) receptor knockout mice and wild-type mice treated with a novel Avpr1b receptor antagonist.","date":"2010","source":"Journal of neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20846299","citation_count":23,"is_preprint":false},{"pmid":"19492333","id":"PMC_19492333","title":"Cloning and expression of the gene for an insect haemocyte anti-aggregation protein (VPr3), from the venom of the endoparasitic wasp, Pimpla hypochondriaca.","date":"2009","source":"Archives of insect biochemistry and physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19492333","citation_count":18,"is_preprint":false},{"pmid":"23580725","id":"PMC_23580725","title":"The effect of vasopressin 1b receptor (V1bR) blockade on HPA axis activity in rats exposed to acute heat stress.","date":"2013","source":"The Journal of experimental biology","url":"https://pubmed.ncbi.nlm.nih.gov/23580725","citation_count":17,"is_preprint":false},{"pmid":"35451730","id":"PMC_35451730","title":"Responsiveness to DDAVP in Cushing's disease is associated with USP8 mutations through enhancing AVPR1B promoter activity.","date":"2022","source":"Pituitary","url":"https://pubmed.ncbi.nlm.nih.gov/35451730","citation_count":16,"is_preprint":false},{"pmid":"22341483","id":"PMC_22341483","title":"Association between functional polymorphism of the AVPR1b gene and polymorphism rs1293651 of the CRHR1 gene and bipolar disorder with psychotic features.","date":"2012","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22341483","citation_count":16,"is_preprint":false},{"pmid":"23962971","id":"PMC_23962971","title":"Epistatic interaction between CRHR1 and AVPR1b variants as a predictor of major depressive disorder.","date":"2013","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23962971","citation_count":14,"is_preprint":false},{"pmid":"25309987","id":"PMC_25309987","title":"Clock gene modulates roles of OXTR and AVPR1b genes in prosociality.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25309987","citation_count":10,"is_preprint":false},{"pmid":"19486526","id":"PMC_19486526","title":"A complex selection signature at the human AVPR1B gene.","date":"2009","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/19486526","citation_count":10,"is_preprint":false},{"pmid":"25438555","id":"PMC_25438555","title":"[Arginine-vasopressin receptor gene (AVPR1A, AVPR1B) polymorphisms and their relation to personality traits].","date":"2014","source":"Genetika","url":"https://pubmed.ncbi.nlm.nih.gov/25438555","citation_count":4,"is_preprint":false},{"pmid":"39501331","id":"PMC_39501331","title":"Implication of vasopressin receptor genes (AVPR1A and AVPR1B) in the susceptibility to polycystic ovary syndrome.","date":"2024","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/39501331","citation_count":2,"is_preprint":false},{"pmid":"36367618","id":"PMC_36367618","title":"Correlation Between Sleep Electroencephalogram, Brain-Derived Neurotrophic Factor, AVPR1B Gene Polymorphism, and Suicidal Behavior in Patients with Depression.","date":"2022","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/36367618","citation_count":2,"is_preprint":false},{"pmid":"39217353","id":"PMC_39217353","title":"V1bR enhances glucose-stimulated insulin secretion by paracrine production of glucagon which activates GLP-1 receptor.","date":"2024","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/39217353","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":11282,"output_tokens":1687,"usd":0.029576},"stage2":{"model":"claude-opus-4-6","input_tokens":4937,"output_tokens":1876,"usd":0.107378},"total_usd":0.136954,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"AVPR1B (Avpr1b) receptor on anterior pituitary corticotrophs mediates AVP-stimulated ACTH release; pharmacological antagonism or genetic knockout of Avpr1b significantly reduces plasma ACTH (and corticosterone) responses to acute restraint and forced swimming stress, demonstrating its essential role in HPA axis activation.\",\n      \"method\": \"Avpr1b knockout mice compared to wild-type; pharmacological antagonism with a selective Avpr1b antagonist; plasma ACTH and corticosterone measurement by ELISA\",\n      \"journal\": \"Journal of neuroendocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal genetic KO and pharmacological blockade with defined neuroendocrine phenotype, replicated across two stressor paradigms\",\n      \"pmids\": [\"20846299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Avpr1b in the dorsal hippocampus mediates anxiety-related behavior (open-arm avoidance in elevated plus-maze); selective Avpr1b antagonist (SSR 149415) microinfused into the dorsal (but not ventral) hippocampus reduced anxiety-like behavior, while Avpr1a antagonism had the opposite regional specificity (ventral but not dorsal hippocampus).\",\n      \"method\": \"Intra-hippocampal microinfusion of selective receptor antagonists; elevated plus-maze and shock-probe burying behavioral tests in rats\",\n      \"journal\": \"Neuropeptides\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization-function experiment with pharmacological dissection, single lab\",\n      \"pmids\": [\"18508119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"AVPR1B is dramatically upregulated in pituitary corticotropinoma cells relative to normal pituitary, and desmopressin (a synthetic AVP receptor agonist) directly stimulates ACTH secretion, intracellular Ca2+ mobilization, and proliferation exclusively in corticotropinoma cells via AVPR1B; an AVPR1B antagonist completely blocked these stimulatory effects.\",\n      \"method\": \"Quantitative RT-PCR for AVPR expression; primary cultures of corticotropinoma and other pituitary adenoma cells treated with desmopressin; ACTH secretion assay; [Ca2+]i kinetics; AVPR1B antagonist blockade\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal assays (qPCR, Ca2+ imaging, ACTH secretion, pharmacological blockade) in primary human tumor cells\",\n      \"pmids\": [\"23884782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"V1bR (AVPR1B) blockade with the selective antagonist Nelivaptan reduces the increase in blood ACTH caused by acute heat stress in rats, directly confirming AVP's positive role in regulating ACTH secretion from the pituitary via V1bR; heat exposure also decreased intrapituitary V1bR protein levels.\",\n      \"method\": \"Pharmacological blockade with Nelivaptan (selective V1bR antagonist) in rats; circulating ACTH and corticosterone by ELISA/chemiluminescence; intrapituitary ACTH and V1bR protein by western blot\",\n      \"journal\": \"The Journal of experimental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological blockade with defined neuroendocrine readout, single lab\",\n      \"pmids\": [\"23580725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"USP8 mutations in corticotropinomas enhance AVPR1B promoter activity, leading to upregulation of AVPR1B expression and increased ACTH responsiveness to desmopressin (DDAVP); mutant USP8 overexpression increases Avpr1b promoter activity compared to wild-type USP8.\",\n      \"method\": \"Quantitative RT-PCR and immunohistochemistry for AVP receptor expression; dual-luciferase reporter assay for Avpr1b promoter activity with mutant vs. wild-type USP8 overexpression\",\n      \"journal\": \"Pituitary\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay with functional USP8 mutant/WT comparison, single lab\",\n      \"pmids\": [\"35451730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"AVPR1B (V1bR) is expressed exclusively in pancreatic alpha cells (not beta cells); activation of V1bR by AVP stimulates alpha cells to secrete glucagon, which then promotes glucose-dependent insulin secretion from beta cells in a paracrine manner by activating GLP-1R (not GCGR), revealing an AVP/V1bR → glucagon → GLP-1R crosstalk between alpha and beta cells.\",\n      \"method\": \"Single-cell transcriptome analysis for receptor localization; V1bR selective antagonist blockade; islet vs. isolated beta-cell insulin secretion assays; glucagon measurement; GLP-1R vs. GCGR antagonist experiments\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (scRNA-seq, pharmacological, cell-type-specific assays), single lab\",\n      \"pmids\": [\"39217353\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"AVPR1B encodes a G protein-coupled vasopressin receptor expressed on anterior pituitary corticotrophs (where it mediates AVP-stimulated ACTH release and HPA axis activation during stress), in hippocampal neurons (where dorsal hippocampal AVPR1B modulates anxiety-like behavior), and in pancreatic alpha cells (where it triggers glucagon secretion that promotes paracrine GLP-1R-dependent insulin release from beta cells); in corticotropinomas, AVPR1B is dramatically upregulated—an effect enhanced by USP8 mutations that increase AVPR1B promoter activity—making it the primary mediator of desmopressin-induced ACTH hypersecretion in Cushing's disease.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"AVPR1B is a Gq/11-coupled vasopressin receptor that functions as a critical mediator of hypothalamic-pituitary-adrenal (HPA) axis activation and paracrine hormone signaling in the endocrine pancreas. In anterior pituitary corticotrophs, AVPR1B mediates arginine vasopressin (AVP)-stimulated ACTH release, and its genetic knockout or pharmacological antagonism significantly attenuates plasma ACTH and corticosterone responses to acute stress [PMID:20846299, PMID:23580725]. AVPR1B is dramatically upregulated in corticotropinomas—an effect potentiated by USP8 mutations that enhance AVPR1B promoter activity—where it drives desmopressin-stimulated ACTH hypersecretion, intracellular Ca²⁺ mobilization, and cell proliferation [PMID:23884782, PMID:35451730]. In pancreatic islets, AVPR1B is expressed exclusively in alpha cells, where its activation by AVP stimulates glucagon secretion that promotes glucose-dependent insulin release from beta cells through a paracrine GLP-1R-dependent mechanism [PMID:39217353].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"The question of where in the brain AVPR1B acts to regulate anxiety was addressed by showing that dorsal hippocampal AVPR1B mediates anxiety-like behavior, establishing region-specific functional roles for vasopressin receptor subtypes.\",\n      \"evidence\": \"Intra-hippocampal microinfusion of selective AVPR1B antagonist (SSR 149415) with elevated plus-maze and shock-probe behavioral tests in rats\",\n      \"pmids\": [\"18508119\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single lab finding; independent replication in additional behavioral paradigms needed\",\n        \"Downstream signaling cascades in hippocampal neurons not characterized\",\n        \"Whether dorsal hippocampal AVPR1B affects HPA axis feedback remains untested\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The necessity of AVPR1B for stress-induced HPA axis activation was established by demonstrating that both genetic knockout and pharmacological antagonism of Avpr1b markedly reduce ACTH and corticosterone responses to acute stress.\",\n      \"evidence\": \"Avpr1b knockout mice and selective V1bR antagonist treatment with plasma ACTH/corticosterone measurement across restraint and forced-swim stress paradigms\",\n      \"pmids\": [\"20846299\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether AVPR1B is required for chronic stress responses not addressed\",\n        \"Intracellular signaling pathway (Gq, Ca²⁺, PKC) in corticotrophs not dissected in vivo\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"AVPR1B was identified as the key receptor mediating desmopressin-induced ACTH hypersecretion in human corticotropinomas, explaining why the desmopressin stimulation test selectively detects Cushing's disease: AVPR1B is massively overexpressed in corticotropinomas relative to normal pituitary.\",\n      \"evidence\": \"qRT-PCR for receptor expression, primary corticotropinoma cell cultures with desmopressin stimulation, ACTH secretion assays, intracellular Ca²⁺ imaging, and AVPR1B antagonist blockade; corroborated by V1bR antagonist Nelivaptan reducing heat-stress-induced ACTH in rats\",\n      \"pmids\": [\"23884782\", \"23580725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism driving AVPR1B upregulation in tumors was not yet identified\",\n        \"Whether AVPR1B-mediated proliferation is sufficient for tumorigenesis remains unknown\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A mechanism for AVPR1B overexpression in corticotropinomas was revealed: recurrent USP8 mutations enhance AVPR1B promoter activity, linking a frequent somatic driver mutation to the receptor upregulation underlying desmopressin responsiveness.\",\n      \"evidence\": \"Dual-luciferase reporter assay comparing mutant vs. wild-type USP8 effects on Avpr1b promoter activity; qRT-PCR and immunohistochemistry in tumor samples\",\n      \"pmids\": [\"35451730\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single-lab reporter assay; independent validation and identification of the transcription factor intermediaries needed\",\n        \"Whether USP8-driven AVPR1B upregulation is necessary and sufficient for desmopressin sensitivity in vivo not shown\",\n        \"The direct USP8 substrate linking deubiquitination to AVPR1B promoter activation is unidentified\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"AVPR1B function was extended beyond the pituitary and brain by showing it is the exclusive vasopressin receptor in pancreatic alpha cells, where it triggers glucagon release that drives paracrine GLP-1R-dependent insulin secretion from beta cells.\",\n      \"evidence\": \"Single-cell transcriptomics for receptor localization; islet vs. isolated beta-cell insulin secretion assays; V1bR, GLP-1R, and GCGR selective antagonist experiments\",\n      \"pmids\": [\"39217353\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single-lab finding; in vivo confirmation of AVP/AVPR1B-glucagon-GLP-1R axis in glucose homeostasis needed\",\n        \"Physiological relevance under fasting vs. fed states not delineated\",\n        \"Whether AVPR1B in alpha cells contributes to diabetes pathophysiology is unexplored\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of AVPR1B selective agonism/antagonism, the full downstream signaling network in corticotrophs (beyond Ca²⁺ mobilization), and the therapeutic potential of AVPR1B-targeted therapy in Cushing's disease and metabolic disorders remain to be established.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No high-resolution structure of AVPR1B in complex with ligand or G protein is available\",\n        \"Complete Gq/Ca²⁺/PKC signaling cascade in corticotrophs not mapped\",\n        \"Clinical efficacy of selective AVPR1B antagonists in Cushing's disease not demonstrated\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 5]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"USP8\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}